Drug news
Merck Inc files MK 3641 at FDA for treatment of Ragweed Pollen Allergies
Merck & Co. has announced that the FDA has accepted its biologics license application for MK 3641, a dissolvable tablet to treat Ragweed Pollen Allergies and expects the agency to complete its review in the first half of 2014.
Merck has partnered with ALK-Abello A/S to develop the sublingual allergy immunotherapy tablets for ragweed.